OBBBA’s new Section 168(n) lets manufacturers expense qualifying facility costs – if timing, use, and documentation line up. Cost seg helps.
By Michael Webb and Ed Meyette
Manufacturers – including life sciences and pharmaceutical manufacturers – know that capital projects live or die on cash flow . The One Big Beautiful Bill Act (OBBBA) reshaped that math by restoring 100% bonus depreciation for most qualifying tangible property and creating qualified production property (QPP) under IRC Section 168(n) – a new way to immediately expense certain portions of nonresidential buildings tied directly to U.S. production.
The opportunity is significant, but QPP is not “my building is a factory, therefore 100% depreciation.” It is an election layered on top of definitional tests (“integral to production,” “substantial transformation,” “begin construction”) and cost-allocation work. The manufacturers that treat this as a coordinated engineering plus tax plus fixed-asset process are the ones most likely to capture the full benefit and defend it.
The OBBBA effectively gives manufacturers two separate acceleration tools:
Both tools might deliver a 100% first-year deduction, but the timing rules, elections, and recapture risks are different – so modeling and documentation matter.
At a high level, QPP is the portion of a nonresidential building that is:
What’s excluded is just as important: QPP does not include building areas used for offices, administrative services, lodging, parking, sales, research, software engineering or engineering activities, or other functions not integral to production. There also is a lessor exclusion – leased property is not treated as used by the lessor for QPP purposes.
For modern manufacturing campuses with production, research and development (R&D), engineering, and offices under one roof, QPP turns into a portion problem: Taxpayers must isolate what is integral to production and support the allocation.

Bonus depreciation is claimed in the year property is placed in service – when it is ready and available for its intended use – often later than when it is purchased or delivered.
The OBBBA adds an additional timing layer. For Section 168(k), the bonus percentage can depend on when property is treated as acquired (often tied to a written binding contract). For self-constructed property, “acquired” might effectively tie back to when construction is treated as having begun – concepts that manufacturers might recognize from earlier bonus depreciation transition rules. Note that taxpayers currently are awaiting guidance clarifying the ” beginning of construction” issue.
For QPP, the “begin construction” date is a gatekeeper. If a project’s construction is deemed to have begun before the statutory start date, the facility might be outside the QPP window – even if it is placed in service later. That makes contemporaneous documentation nonnegotiable: notices to proceed, binding contract terms (including cancellation rights), invoices for all costs incurred prior to Jan. 20, 2025, job logs, inspection records, and site photos.
A common misconception is that cost segregation doesn’t matter if a building can be expensed under QPP.
In practice, QPP often increases the value of cost segregation because there are two different allocation tasks:
When coordinated, the following can help:
Life sciences capital projects often are among the most capital intensive and schedule sensitive i n manufacturing: clean rooms, sterile fill-finish suites, bioprocessing areas, active pharmaceutical ingredient (API) plants, and packaging expansions. QPP can materially change the after-tax cost of these projects in the United States when qualifying areas are integral to producing a product through substantial transformation.
This becomes a practical consideration in the way regulated facilities are designed: production suites and process support spaces sit next to quality labs, engineering offices, and R&D. Section 168(n) is a portion rule, so eligibility is won or lost based on how well an organization separates qualifying production areas from excluded uses and supports the allocation with drawings and cost details.
Examples to consider early (facts and future guidance will matter):
Areas that frequently require careful carve-outs:
Also keep “placed in service” in mind . In pharma and biotech, readiness can be tied to commissioning, qualification, and validation (CQV) milestones. Align the tax placed-in-service analysis with the project’s CQV documentation so the deduction year is defensible.
The OBBBA created a powerful pairing for manufacturers: restored 100% bonus depreciation under Section 168(k) and a new, targeted 100% expensing tool for qualifying facility real property under Section 168(n). The value is real, but it is unlocked through disciplined timing analysis, credible use allocations, and documentation that can survive scrutiny.
For many manufacturers, the most effective approach is coordinated among business areas: engineering and operations define use, tax defines eligibility and elections, and cost segregation specialists translate that reality into defensible asset classifications and allocations.
About the Authors:
Michael Webb is a senior manager in the Crowe LLP national federal tax consulting services (FTCS) group and supports clients to provide fixed asset, accounting method, and clean energy solutions in a variety of industries.
Ed Meyette is a partner in the Crowe LLP national tax services group and leads the firm’s fixed asset solutions group.
Read more:
Power Lunch: The Tax Side of Capital Spending | Crowe Insights, 2/12/2025
Year-End Hot Topics in Tax | Crowe Insights, 12/16/2025
Scott Ellyson, CEO of East West Manufacturing, brings decades of global manufacturing and supply chain leadership to the conversation. In this episode, he shares practical insights on scaling operations, navigating complexity, and building resilient manufacturing networks in an increasingly connected world.